[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 6 sources · 24 days · First seen · Last updated

Advancements in obesity and diabetes medications

Overview

Developments in obesity and diabetes treatments have focused on both regulatory approvals and clinical efficacy data. In Brazil, the National Health Surveillance Agency (Anvisa) approved generic registrations for liraglutide, a GLP-1 receptor agonist manufactured by EMS. These generic subcutaneous injectable solutions are intended to reduce costs for obesity and type 2 diabetes patients by being priced at least 35% lower than reference products.

Concurrently, clinical data presented at the EASD 2026 congress highlighted advancements in metabolic health and weight reduction. Phase 3 trials for retatrutide showed participants achieving an average weight loss of 28.3% over 80 weeks, with some studies showing significant reductions in HbA1c levels for type 2 diabetes patients. Additionally, the combination treatment CagriSema demonstrated weight loss efficacy in both obesity and diabetes studies, while also impacting neurological hunger cues and ‘food noise’.

Entities

Milan · EMS · European Association for the Study of Diabetes · Anvisa

Timeline

  1. [HEALTH] 3 sources
    Obesity drugs show up to 30% weight loss at EASD 2026

    New data from the EASD 2026 congress in Milan shows obesity drugs like retatrutide and CagriSema can achieve weight loss of nearly 30% while reducing hunger and improving metabolic health.

  2. [HEALTH] 3 sources
    Anvisa approves generic obesity and diabetes medications from EMS

    Anvisa has approved two generic liraglutide medications from EMS for treating obesity and type 2 diabetes in Brazil, a move expected to increase market competition and lower costs.

Sources

dol.com.br · healthyliving.gr · iatronet.gr · revistadafarmacia.com.br · sbctv.gr · valor.globo.com